Barclays Maintains Overweight on Elevance Health, Raises Price Target to $404

Benzinga · 01/05 14:18
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $385 to $404.